Access and Adherence: Navigating Insurance Coverage and Real-World Barriers to Biomarker Testing in Extrapulmonary Neuroendocrine Carcinoma

In this episode, ‘Access and Adherence: Navigating Insurance Coverage and Real-World Barriers to Biomarker Testing in Extrapulmonary Neuroendocrine Carcinoma,’ the expert oncologists explored the following questions:

Where are most of these biomarker tests performed? If a test is performed in an outpatient setting, how are you ensuring patients are adherent to getting their testing?

What is insurance coverage like for biomarker testing in extrapulmonary neuroendocrine carcinomas?

How are you overcoming any barriers with insurance providers?

The panelists examined where biomarker testing for extrapulmonary neuroendocrine carcinoma (epNEC) is typically performed, noting that tissue-based testing and liquid biopsies offer practical options that generally do not require additional burden on the patient, as tumor samples can be sent directly to commercial vendors or reference laboratories such as Mayo Clinic. Sandy Kotiah, William Oh, Namrata Vijayvergia, and Aman Chauhan discussed the insurance coverage landscape for biomarker testing, highlighting the Medicare 14-day rule following inpatient admission as a particularly problematic barrier for patients with fast-growing tumors who require immediate diagnostic workup and treatment initiation. The panelists also addressed strategies for overcoming coverage barriers, noting that many commercial testing companies do not balance bill patients when claims are denied, and encouraging clinicians to reassure patients accordingly while advocating for policy updates that better reflect the urgency of biomarker-driven care in aggressive cancers.

Throughout the conversation, the experts provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, ‘Unmet Needs and Emerging Mechanisms of Action in Extrapulmonary Neuroendocrine Carcinoma: The Path Toward Better Therapies,’ features the panelists advancing their conversation on extrapulmonary neuroendocrine carcinoma and focusing on the significant unmet needs that have driven development of newer agents, and the novel mechanisms of action currently under investigation that may transform the treatment landscape.